Medtronic plc (MDT) has a MoatMap StockRank of 76/100 based on Quality (62/100), Value (55/100), and Momentum (41/100) factor scores. The current signal is BUY. Medtronic, a global medical device leader, while a generally high-quality business, does not present an unpriced macro inflection point or asymmetric opportunity linked to the fund's specific themes for the next 18 months, despite its durable moat characteristics.
Medtronic plc is a global leader in medical technology, developing, manufacturing, and marketing a broad portfolio of medical devices and therapies for various chronic diseases, including cardiovascular, diabetes, and surgical solutions. The company maintains a strong competitive advantage through its extensive intellectual property, robust R&D pipeline, and deep clinical relationships, driving innovation in patient care worldwide.
| Price | $75.57 |
| Market Cap | $100.9B |
| P/E (TTM) | 21.68 |
| P/E (Forward) | 12.81 |
| Price/Book | 2.03 |
| Return on Equity | 9.4% |
| Return on Invested Capital | 8.1% |
| Debt/Equity | 57.06 |
| Gross Margin | 65.2% |
| Operating Margin | 20.0% |
| Revenue Growth | 8.7% |
| Dividend Yield | 3.7% |
| Free Cash Flow | $4.1B |
Medtronic plc operates in the Medical Devices industry, part of the Healthcare sector (Ireland).